Analysts/Institutional Investor Meet/Con. Call Updates

INNOVA CAPTAB LIMITED Plot No. 320, Industrial Area, Phase-1, Panchkula, Pin-134113, Haryana, India. Phone: +91-172-4194500 14th August, 2026 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Mumbai – 400001 Bandra Kurla Complex BSE Symbol: INNOVACAP Bandra (E), Mumbai – 400051 BSE Scrip Code: 544067 NSE Symbol: INNOVACAP Dear Sir/Madam, Subject: Transcript of the investor/analyst earnings call held on Wednesday, 12th August, 2026 This is in continuation to our letter dated 12th August, 2026, wherein we had informed regarding the audio link of the earnings call with analysts/investors for the quarter ended 30th June, 2026. In this regard, please find enclosed herewith the transcript of the said call. The transcript will also be available on the Company’s website i.e. INNOVA CAPTAB. You are requested to take this information on record. Thanking you, Yours faithfully, For Innova Captab Limited Neeharika Shukla Company Secretary and Compliance Officer Registered Office - 1513, 15th Floor, Satra Plaza CHS Ltd. Plot No. 19&20, Sector-19D, Vashi, Navi Mumbai-400703, Maharashtra, India. CIN - L24246MH2005PLC150371, email - mail@innovacaptab.com “Innova Captab Limited Q1 FY27 Earnings Conference Call” 12th August, 2026 “E&OE - This transcript is edited for factual errors and readability. In case of discrepancy, the audio recordings uploaded on the stock exchange on 12th August 2026 will prevail.” MANAGEMENT: MR. VINAY LOHARIWALA – MANAGING DIRECTOR – INNOVA CAPTAB LIMITED MR. LOKESH BHASIN – CHIEF FINANCIAL OFFICER – INNOVA CAPTAB LIMITED Page 1 of 15 Innova Captab Limited August 12, 2026 Moderator: Ladies and gentlemen, good day, and welcome to Innova Captab Limited Q1 FY27 Earnings Call. As a reminder, all participant lines will be in listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star, then zero on your touchtone phone. Please note that this conference is being recorded. This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions and expectations of the company as on date of this call. These statements are not guarantees of any future performance and involve risks and uncertainties that are difficult to predict. Today, from the management side, we have with us Mr. Vinay Lohariwala, Managing Director, Mr. Lokesh Bhasin, Chief Financial Officer and SGA, Investor Relation Advisor. I now hand the conference over to Mr. Vinay Lohariwala, Managing Director of Innova Captab Limited. Thank you, and over to you, sir. Vinay Lohariwala: Thank you. Good morning, everyone. And thank you for joining us today. It is my pleasure to welcome you all to Innova Captab Q1 FY27 Earnings Conference Call. We have started financial year '27 on a strong note, delivering strong year-on-year growth of 34% and 33% in revenue and EBITDA respectively for the quarter. The performance is broadly in line with growth trajectory we have outlined in the year and provided -- provides further confidence in our ability to deliver on our guidance of 20% revenue growth and profitability outpace revenue for FY27. This performance reflect the continued strength of our diversified business model, disciplined execution, sustained customer traction across the CDMO and branded generic business. Growth during the quarter was supported by steady order flows, an expanding product portfolio and deeper engagement with both existing and new customers. Our continued focus on operational excellence, manufacturing efficiency, and stringent quality standard has enabled us to strengthen our competitive position and effectively address the evolving requirement of our customer across domestic and international markets. Coming to our CDMO business. The CDMO business reported revenue of INR328 crores during Q1 FY27, reflecting a year-on-year growth of 32%. We continue to witness healthy demand across our customer base and our focus remains on strengthening relationships with our existing customers, increasing our share of business with them, and simultaneously adding new customers across therapeutic categories and dosage form. Over the years, we have built a broad and diversified product portfolio supported by strong formulation development capabilities. We continue to invest in product development and complex dosage capabilities, which will enable us to address a wider range of customer requirements and further strengthening our position as a trusted CDMO partner. Our manufacturing capabilities remain a key competitive strength. Page 2 of 15 Innova Captab Limited August 12, 2026 With technologically advanced facilities, increasing automation, robust quality systems and scalable manufacturing platforms, we are well-positioned to support the growing requirement of our customers while maintaining consistency, efficiency and compliance. Coming to our branded generic business. The branded generic business continued to maintain healthy momentum with revenue of INR142 crores, growth of 39% year-on-year basis. Our strategic focus remains focused on strengthening our presence in existing markets and gradually expand into newer domestic and international geographies. We continue to broaden our product offering and deepen market penetration supported by our integrated manufacturing and product development capabilities. Over the medium and long term, we believe the branded generic business provides us the significant opportunity to further diversify our revenue base and strengthen our presence across the key markets. Our long-term focus remains firmly aligned with building Innova Captab into a future-ready, scalable pharmaceutical organization, while maintaining a strong focus on disciplined capital allocation and sustainable value creation. Our strategic priorities remain clear: improving capacity utilization across our manufacturing facilities, expanding our capabilities in complex dosage forms, strengthening our R&D platforms, deepening customer relationships and expanding our branded generic presence across key markets. At the same time, we remain committed to deploying capital in a disciplined and prudent manner with investments being prioritized towards opportunities that offer optimum returns, strengthen our capabilities and competitiveness, support our long-term growth objectives. We remain confident about the opportunities ahead and are committed to creating sustainable long-term value for all our stakeholders. With this, I would like to hand over to call to our CFO, Mr. Lokesh Bhasin, to take you through the financial performance for Q1 FY27. Thank you. Lokesh Bhasin: Thank you, sir. And good morning, everyone. I will now walk you through the financial highlights for Q1 FY27. Q1 FY27 highlights. Our Q1 performance reaffirms the growth trajectory and we remain confident of delivering on our stated growth objectives. With healthy demand across our businesses and continued execution focus, we believe the momentum is sustainable in the future also. Consolidated revenue for the quarter stood at INR470.9 crores, registering a strong 34% year- on-year growth supported by strong demand across both our business areas. Exports contributed 32% of our revenue during this quarter, reflecting the continued progress we are making in expanding our presence across international markets. Our CDMO business reported revenue of INR328.7 crores, growing by 32% year-on-year. The growth was driven by an expanding product portfolio, addition of new customers, and deeper engagement with existing customers, resulting in higher wallet share. Our branded generic business recorded revenue of INR142.2 crores, representing a growth of 39% year-on-year, supported by continued traction across our key markets. Page 3 of 15 Innova Captab Limited August 1 [Showing first 8,000 characters — download PDF for full document]